Tikva Allocell has been selected to present preclinical data on its CD19.SB9.CAR-EBVST program at ACR Convergence 2026, according to FirstWord Pharma. The conference is the annual meeting of the American College of Rheumatology. The company's selection was reported on Thursday, 22 October 2026.
The presentation will cover preclinical-stage findings for the CD19.SB9.CAR-EBVST candidate. Beyond the program name and the meeting at which the data will be shown, FirstWord Pharma's report did not include further detail on the findings themselves.
The disclosure places the program on the agenda of a major rheumatology gathering, where cell-based approaches are among the topics under discussion. Because the material is preclinical, it reflects laboratory work rather than results from testing in patients.
Tikva Allocell has not, in the reporting summarized here, disclosed the full contents of the presentation or the format in which it will be delivered. ACR Convergence 2026 is the venue named for the data, and the company's selection was confirmed in the FirstWord Pharma report.
Readers should watch for the presentation itself at ACR Convergence 2026, where the preclinical results behind the CD19.SB9.CAR-EBVST program are expected to be set out in full.
